title: Novel antiinflammatory therapies for COPD.
abstract: The biologic nature of COPD inflammation is not well understood and agents that inhibit inflammation in COPD are a major unmet need. However, a variety of agents that have the potential to be inhibitors of COPD inflammation are in various stages of development. Agents that have been approved for a non-COPD indication but that have potential for inhibiting COPD inflammation include the statins, some phosphodiesterase inhibitors, some long-acting β agonists, tiotropium bromide, the peroxisome proliferator-activated receptor-γ agonist rosiglitazone, and various monoclonal antibodies. New molecular entities that are being developed specifically as antiinflammatory agents for COPD include a variety of chemokine receptor antagonists, inhibitors of matrix metalloproteinases, inhibitors of p38 mitogen-activated protein kinases, and stem cells. Some other novel agents that are in preclinical or early clinical stages are mentioned.
authors.affiliation: Pulmonary Division, Department of Medicine, St. Francis Hospital, Hartford, CT; Stritch-Loyola School of Medicine, Chicago, IL. Electronic address: grossnicholas1@gmail.com.
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Gross
mesh_terms: D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D018680:Cholinergic Antagonists / Q000494:pharmacology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D007004:Hypoglycemic Agents / Q000494:pharmacology; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000473:pathology; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors; D019714:Tissue Inhibitor of Metalloproteinases / Q000494:pharmacology; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors
chemical_list: D000318:Adrenergic beta-Agonists; D000893:Anti-Inflammatory Agents; D018680:Cholinergic Antagonists; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D016859:Lipoxygenase Inhibitors; D010726:Phosphodiesterase Inhibitors; D019707:Receptors, Chemokine; D019714:Tissue Inhibitor of Metalloproteinases; D048051:p38 Mitogen-Activated Protein Kinases